Electromed
Electromed's revenue rose 15.3% to $74 million in fiscal 2026. Its operating margin was 18.8%, up from 15.1% a year earlier. Free cash flow was $8 million, down 24.4%. It paid out $4 million in dividends and buybacks, 47% of free cash flow. The diluted share count fell 2.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Electromed does
Electromed makes and sells the SmartVest Airway Clearance System, which helps people with weak lung function clear mucus from their airways. The system has an air pulse generator, a vest or wrap worn on the upper body and a hose that links them. The pulses shake the chest wall, a therapy called high frequency chest wall oscillation. It is meant to be used at home, and it comes in sizes for children and adults.
Electromed mainly sells directly to patients and their doctors. It gets referrals from clinicians, bills insurers for the patient, delivers the system and trains the patient to use it at home. It says this lets it skip the usual home medical equipment dealers. It also sells to hospitals for patients after surgery, in intensive care or with lung infections, and sells through distributors abroad.
Its homecare revenue comes from commercial insurers, Medicare, Medicaid, Veterans Affairs and direct patient payments. The company was incorporated in Minnesota in 1992, is listed on the NYSE American, and had 197 employees on June 30, 2026.
Its biggest risks, as it describes them
- Its homecare revenue depends on insurers and government programs agreeing to reimburse the cost of its devices.
- The availability of reimbursement depends on an existing billing code for this type of therapy.
- It relies on referrals from doctors and clinicians to find new patients.
Income statement
From fiscal 2017 to 2026, earnings per share grew 19.6% a year and net income 19.9% a year, as new shares raised the share count by 2% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 8 | 7 | 16 | 15 | 20 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.8x | 4.7x | 5.8x | 4.3x | 4.7x |
| Quick ratio | 4.4x | 4.2x | 5.3x | 4.0x | 4.4x |
Cash flow
Projections
Project Electromed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Electromed shares on the open market, and 3 insiders sold $2.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | James L. CunniffCEO and President, Director | Sold | 9,700 | $36.51 | $354,104 | Form 4 |
| Jun 4, 2026 | Bradley M. NagelChief Financial Officer | Sold | 11,801 | $36.35 | $428,988 | Form 4 |
| May 15, 2026 | Kathleen SkarvanDirector | Sold | 40,000 | $35.48 | $1.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 29.9% | 34.4% | 26.7% |
| Altman Z'' | 12.99 | 10.99 | 11.89 |
| Accruals ratio | −8.0% | −7.3% | 2.7% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Electromed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Electromed | FY26 | 15.3% | 18.8% | 11.4% | — | — | — | |
| AVITA Medical | FY25 | 11.4% | −59.4% | −45.0% | −354.1% | — | 2 | Compare |
| EDAP TMS | FY25 | 1.6% | −35.0% | — | −83.4% | — | — | Compare |
| Sight Sciences | FY25 | −3.1% | −48.0% | −38.7% | — | — | 5 | Compare |
| Pro Dex | FY26 | 16.4% | 16.8% | 8.7% | 19.6% | 0.6x | 7 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 26 | 28 | 31 | 32 | 36 | 42 | 48 | 55 | 64 | 74 |
| Revenue growth | 12.5% | 9.5% | 10.6% | 3.7% | 10.1% | 16.5% | 15.4% | 13.8% | 17.0% | 15.3% |
| Gross profit | 21 | 22 | 24 | 25 | 27 | 31 | 36 | 42 | 50 | 58 |
| Research and development | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Operating income | 4 | 3 | 3 | 5 | 3 | 3 | 4 | 7 | 10 | 14 |
| Net income | 2 | 2 | 2 | 4 | 2 | 2 | 3 | 5 | 8 | 11 |
| Diluted EPS (US$) | 0.26 | 0.21 | 0.23 | 0.47 | 0.27 | 0.26 | 0.36 | 0.58 | 0.85 | 1.30 |
| Diluted shares (millions) | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Cash flow | ||||||||||
| Cash from operations | 1 | 2 | 3 | 4 | 3 | −1 | 1 | 9 | 11 | 10 |
| Capital expenditure | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 1 |
| Free cash flow | 1 | 2 | 1 | 3 | 3 | −2 | −0 | 9 | 11 | 8 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 10 | 4 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 6 | 8 | 8 | 10 | 12 | 8 | 7 | 16 | 15 | 20 |
| Debt incl. finance leases | 1 | — | — | — | — | — | — | — | — | — |
| Total assets | 23 | 27 | 29 | 33 | 37 | 41 | 46 | 52 | 54 | 66 |
| Total liabilities | 4 | 5 | 4 | 3 | 5 | 7 | 8 | 8 | 11 | 12 |
| Shareholders' equity | 20 | 23 | 26 | 30 | 32 | 34 | 38 | 44 | 43 | 54 |
| Margins and ratios | ||||||||||
| Gross margin | 79.5% | 76.9% | 76.2% | 77.6% | 76.4% | 75.5% | 76.0% | 76.3% | 78.1% | 78.5% |
| Operating margin | 13.8% | 9.6% | 9.0% | 15.8% | 8.8% | 7.1% | 8.3% | 12.0% | 15.1% | 18.8% |
| Net margin | 8.6% | 6.5% | 6.3% | 12.8% | 6.6% | 5.5% | 6.6% | 9.4% | 11.8% | 15.3% |
| Free cash flow margin | 2.2% | 6.8% | 4.0% | 10.3% | 7.8% | −5.1% | −0.7% | 16.1% | 17.4% | 11.4% |
| Rule of 40 (growth + FCF margin) | 14.7% | 16.2% | 14.6% | 14.1% | 17.9% | 11.4% | 14.7% | 29.9% | 34.4% | 26.7% |
| Return on capital | 16.2% | — | — | — | — | — | — | — | — | — |
| Return on equity | 12.3% | 8.6% | 8.2% | 14.9% | 7.5% | 6.9% | 8.8% | 12.5% | 17.2% | 23.3% |
| Return on assets | 10.2% | 7.3% | 7.0% | 13.3% | 6.7% | 5.9% | 7.3% | 10.5% | 14.2% | 18.8% |
| Net debt to EBITDA | −1.0x | — | — | — | — | — | — | — | — | — |